Tocilizumab-aazg (Tyenne)
Dilution requiredFull monograph review pending
U.S. label preparation
Tyenne · Dilution required
- Preparation
- Use the IV concentrate and 0.9% or 0.45% sodium chloride. Use a 50 mL bag or bottle below 30 kg and 100 mL at or above 30 kg. Remove and discard a volume of diluent equal to the volume of concentrate to be added.
- Administration and handling
- Add the prescribed volume slowly and invert gently. Infuse over 60 minutes. Check the indication and age-specific dosage in the label.
Product and source details
Fresenius Kabi USA, LLC · BLA761275
Product NDC: 65219-590, 65219-592, 65219-594
SPL effective 2026-05-15 | SPL version 3. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.